The trial showed reduced disease activity [108] and the FDA approved tocilizumab in 2010 for the treatment of RA patients refractory to TNF inhibitors; additionally it was also shown efficient in another trial for the treatment of SJIA [109] where in 2011 the FDA expanded the use of the antibody to include the treatment of SJIA patients. This evidence concerns the gene TNF and rheumatoid arthritis.